{"id":123460,"date":"2026-06-19T10:05:20","date_gmt":"2026-06-19T04:35:20","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=123460"},"modified":"2026-06-19T10:05:21","modified_gmt":"2026-06-19T04:35:21","slug":"aurobindo-pharma-ftc-lannett-acquisition-june-19-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/aurobindo-pharma-ftc-lannett-acquisition-june-19-2026\/","title":{"rendered":"Aurobindo Pharma Stock Gains Over 1.5% to Rs 1,470 After FTC Conditionally Clears $250 Million Lannett Acquisition; Must Divest 4 Generic Products to Quagen Pharma"},"content":{"rendered":"
<\/div>\n

Aurobindo Pharma Rs 1,461.40 (+1.23%; day high Rs 1,470\/+1.82%) on 19 Jun 2026. FTC clears $250M Lannett acquisition with conditions: must divest 4 generic products to Quagen Pharma.<\/em><\/p>\n

Aurobindo Pharma share price gained over 1.5% to a day high of Rs 1,470 on 19 June 2026 after the US Federal Trade Commission cleared the company’s $250 million acquisition of Pennsylvania-based Lannett Company through a consent order that requires Aurobindo Pharma to divest four generic drug products to Quagen Pharmaceuticals LLC, a New Jersey-based generics maker, to resolve anticompetitive concerns. The FTC’s conditional clearance removes a key regulatory hurdle for Aurobindo’s most significant US acquisition in recent years, which gives it a manufacturing base in Indiana, entry into the attention-deficit\/hyperactivity disorder medication market and a reshoring positioning ahead of anticipated US pharmaceutical tariffs.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n